Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation

Table 2 Procedural and in-hospital outcomes (n = 17) n (%)

	AF group	Non-AF group	P
Valve size (mm)			0.27
23	13 (76.5)	10 (58.8)
26	4 (23.5)	7 (41.2)
Access			0.55
Transfemoral	16 (94.1)	15 (88.2)
Transapical	1 (5.9)	2 (11.8)
Procedural success	16 (94.1)	17 (100)	0.31
Any peri-procedural complication	7 (41.2)	7 (41.2)	1.00
Death	2 (11.8)	2 (11.8)	1
Emergent heart surgery	0	1 (5.9)	0.31
Orotracheal intubation > 24 h	0	1 (5.9)	0.31
Proshtesis embolization	0	0	-
Endocarditis	0	0	-
New onset AF	1 (5.9)	1 (5.9)	1.00
Coronary obstruction	1 (5.9)	1 (5.9)	1.00
Myocardial infarction	1 (5.9)	1 (5.9)	1.00
Stroke	0	0	-
Renal failure requiring hemodialysis	0	0	-
New pacemaker implantation	2 (11.8)	1 (5.9)	0.55
Major access site complications	0	2 (11.8)	0.14
Minor access site complications	2 (11.8)	4 (23.5)	0.37
Transfusion	5 (29.4)	2 (11.8)	0.20
Post-procedural stay (mean days)	14.4	10.2	0.22

AF: Atrial fibrillation.